Kirkland & Ellis advised Antylia Scientific, a diversified life science tools business and portfolio company of GTCR, a leading private equity firm, on the sale of its Masterflex business unit to Avantor for $2.9 billion. Masterflex is a market leader in peristaltic and single-use bioprocessing solutions. Following the sale of the Masterflex business unit, GTCR and other equity holders will continue to own Antylia and its remaining assets, which include its portfolio of life sciences products. The transaction is expected to close in the fourth quarter of 2021 and is subject to customary closing conditions.
The Kirkland team was led by corporate partners Michael Weed, Christopher Thomas and Sandy Perl and associates Matt Whited and Andrew Struckmeyer, technology & IP transactions partner Aaron Lorber and associate Matt Darch, and tax partners Gregory Gallagher and Polina Liberman.